Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2015.08.194 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of coronary artery tortuosity on outcomes following stenting with newer-generation drug-eluting stents. An analysis of the randomized BIOFLOW trials.
Rev Esp Cardiol (Engl Ed)
January 2025
Department of Cardiology, Internal Medicine II, Medical University of Vienna, Vienna, Austria. Electronic address:
Introduction And Objectives: Patients undergoing percutaneous coronary intervention in vessels with moderate-to-severe tortuosity are at higher risk of adverse outcomes, but data are scarce in the era of newer-generation stents. We compared outcomes following percutaneous coronary intervention in vessels with moderate-to-severe tortuosity using a bioresorbable-polymer sirolimus-eluting stent (BP-SES) vs a durable-polymer everolimus-eluting stent.
Methods: A total of 2350 patients from the BIOFLOW II, IV, and V randomized trials were stratified into 2 groups based on target-vessel tortuosity: none-to-mild and moderate-to-severe.
Preclinical evaluation of the sirolimus-eluting iron bioresorbable scaffold in canine below-the-knee artery.
Int J Cardiol
February 2025
Department of Vascular and Endovascular Surgery, First Medical Center of Chinese PLA General Hospital, Beijing 100853, China. Electronic address:
Article Synopsis
- This study investigates the effectiveness of bioresorbable scaffolds (IBS) versus everolimus-eluting stents (EES) for treating below-the-knee arterial disease in dogs, focusing on their support performance and effects on tissue.
- Both types of implants were successfully used, showing similar levels of arterial narrowing within the first six months, but the IBS scaffold exhibited gradual corrosion over time.
- Overall, the findings indicate that the IBS is comparable to EES in terms of support and tissue response within 6 months, while demonstrating a manageable corrosion profile over a year.
Long-Term Clinical Outcomes of Biodegradable- Versus Durable-Polymer-Coated Everolimus-Eluting Stents in Real-World Post-Marketing Study.
Catheter Cardiovasc Interv
November 2024
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA.
Background: Long-term clinical data on biodegradable-polymer (BP) drug-eluting stents (DES) are limited. The objective of this study was to assess the long-term safety and efficacy of the BP-DES SYNERGY compared to XIENCE V, a durable-polymer (DP)-DES.
Methods: We compared patients treated with BP-DES or DP-DES at our center from 2008 to 2020.
Characteristics and outcomes of patients with stent implantation for coronary artery lesions caused by Kawasaki disease - insights from second-generation stent implantation.
Cardiol Young
October 2024
Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Background: Adult Kawasaki patients may require intervention for occlusive coronary artery disease. Some adverse effects of first-generation drug-eluting stent implantation with sirolimus have been reported in this population.
Methods: A total of nine lesions in eight (seven males, one female) patients who underwent stent implantations in this population between 2000 and 2021 were reviewed.
Assessment of Cutting-Balloon Angioplasty with Novel Bioabsorbable Polymer-Coated Everolimus-Eluting Stent in Treating Calcified Coronary Lesions Guided by Intravascular Ultrasound (CUPID Trial): study design and protocol.
Trials
October 2024
Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
Article Synopsis
- A multicenter study is assessing the safety and effectiveness of a cutting balloon angioplasty combined with a bioabsorbable polymer-coated everolimus-eluting stent for treating calcified coronary artery lesions in patients.
- The trial involves comparing the cutting balloon (Wolverine™) to a non-compliant balloon in a group of 250 patients who have received the Synergy™ stent, focusing on outcomes like stent area, major cardiac events, and operational metrics.
- The research aims to validate the use of cutting balloons for a range of calcified lesions, potentially influencing insurance coverage for these procedures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!